-

Guardant Health to Report Third Quarter 2024 Financial Results on November 6, 2024

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, November 6, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event.

About Guardant Health

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

Contacts

Investor Contact:
Zarak Khurshid
investors@guardanthealth.com

Media Contact:
Melissa Marasco
press@guardanthealth.com
+1 650-647-3711

Guardant Health, Inc.

NASDAQ:GH

Release Versions

Contacts

Investor Contact:
Zarak Khurshid
investors@guardanthealth.com

Media Contact:
Melissa Marasco
press@guardanthealth.com
+1 650-647-3711

More News From Guardant Health, Inc.

Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced preliminary, unaudited results for the quarter and full year ended December 31, 2025. Fourth quarter 2025 preliminary unaudited financial results For the three-month period ended December 31, 2025, as compared to the same period of 2024: Total revenue of approximately $280 million, an increase of 39% Reported approximately 79,000 oncology tests, an increase of 38% Report...

Guardant Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Guardant Health’s management is scheduled to present and participate in a Q&A session on Monday, January 12, at 3:45 p.m. Pacific Time / 6:45 p.m. Eastern Time. Interested parties may access live and archived webcasts of the sessions on the “Investors” section...

Guardant Health to Participate in Upcoming Investor Conferences

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. Jefferies Global Healthcare Conference in London, UK Fireside chat on Wednesday, November 19 at 9:30 a.m. Greenwich Mean Time Piper Sandler 37th Annual Healthcare Conference in New York, NY Fireside chat on Tuesday, December 2 at 8:30 a.m. Eastern Time Interested parties may access live and archived...
Back to Newsroom